Actualidad

Publicaciones científicas

Nuestros médicos oncólogos e investigadores expertos del laboratorio son conferenciantes, a la vez que organizadores de muchos de los más importantes seminarios y reuniones científicas del mundo.

Hemos publicado los resultados de investigaciones propias y en colaboración con las instituciones internacionales más prestigiosos en revistas de reconocido ámbito médico como: New England Journal of Medicine, Clinical Cancer Research, y muchas otras.

Insights in EGFR- mutations and oncogenic KRAS mutations in non-small cell lung cancer” Cancers 2023 May; 15(9): 2519. IF: 6.639

“Biological insights in non- small cell lung cancer” Cancer Biol Med 2023. IF: 5.347

The role of biomarkers in stage III non-small cell lung cancer» Expert Review of Respiratory Medicine 2023 Jan-Jun;17(6):469-480. IF: 4.3

“Lung Cancer Organoids as Avatars of Patients With Lung Cancer in the Prediction of Therapeutic Response” JTO Clin Res Rep. 2023 Oct; 4(10):100571. IF: 2.326

“Promising outlook with sugemalimab in non-small-cell lung cancer” Lancet Oncology 2022 Published Online January 14, (Vol 23): 186-187, 2022. IF: 41.316.

“Ablating lung cancer, knowing the tumor better” The Lancet Regional Health – Europe 2022;22: 100494.

“Classification of atypical EGFR mutations in non-small-cell lung cancer” Ann Oncol 2022 Mar 21;S0923-7534(22)00389-1. Vol 33, Issue 6, P571-573, June 01, 2022 IF: 51.769.

“Location of EGFR exon 20 insertions matters” Cancer Cell 2022. IF: 31.743.

“Cemiplimab monotherapy in advanced non-squamous and squamous NSCLC” Lancet 2021. Vol 397 February 13: 557-559. IF: 60.392

“Poziotinib treatment in intractable NSCLC: EGFR and HER2 exon 20 insertion mutation disease” European Journal of Cancer, 2021. IF: 7.275

«Analysis of extracellular vesicle mRNA derived from plasma using the nCounter platform” Sci Rep 11, 3712 (2021). IF: 3.99

“COVID-19 in Melanoma Patients: Results of the Spanish Melanoma Group Registry, GRAVID study” Journal of the American Academy of Dermatology 2021, 84 (5): 1412-1415. IF: 8.277

“Neoadjuvant atezolizumab plus chemotherapy in resectable non-small-cell lung cancer” Lancet Oncol, 2020 Jun; 21(6):736-738. IF: 35. 386

«Targeting MET amplification in EGFR-mutant non-small-cell lung cancer” Lancet Respir Med. 2020 Published online May 22, 2020. IF: 15.780

«Novel molecular targets for the treatment of lung cancer” Curr Opin Oncol 2020 Jan;32(1):37-43. IF: 3.653

“Safety of anti-PD-L1 inhibition in HIV-1-infected cancer patients” (Response letter of A. Dekker). JAMA Oncology 2020. (Accepted). IF: 22.416

“EGFR first- and second-generation TKIs—there is still place for them in EGFR- mutant NSCLC patients” Transl Cancer Res 2019; 8 (Suppl 1): S23-S47 IF: 1.2

“Profile of alectinib for the treatment of ALK-positive Non-Small Cell Lung Cancer (NSCLC): patient selection and perspectives” OncoTargets and Therapy 2019 IF: 2.656

“PIM-1 inhibition with AZD1208 to prevent osimertinibinduced resistance in EGFR-mutation positive non-small cell lung cancer” Journal of Cancer Metastasis and Treatment 2019.

«Human Papillomavirus Infection and Lung Cancer Current Perspectives in Human Papillomavirus” (BOOK CHAPTER) IntechOpen, 2019.

“Avelumab in non-small-cell lung cancer” Lancet Oncol. 2018 Sep 21. pii: S1470-2045(18)30683-1. IF: 36.418

«Gene expression signatures predicting survival and chemotherapy benefit in patients with resected non-small-cell lung cancer” EBioMedicine. 2018 Jul;33:16-17. IF: 6.183

“Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer” Lancet Oncol 2018 (Correspondence). Volume 19, No. 3, e126, March 2018. IF: 33.9

“Inhibition of MEK, a canonical KRAS pathway effector in KRAS mutant NSCLC” Translational Lung Cancer Research TLCR-2018-15

2022
2021
2020
2019
2018